Castle Biosciences updates its melanoma test data, shares in biotech focus

Castle Biosciences has provided new real-world data on its DecisionDx-Melanoma prognostic test in a peer-reviewed journal, keeping the Nasdaq-listed biotech on the radar of healthcare investors. The stock trades on Nasdaq as part of the wider US biotech space.

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-26, 21:23.

Castle Biosciences (US14843C1053) has come back into focus after highlighting new clinical utility data for its DecisionDx-Melanoma test in a peer-reviewed journal article. The company, whose stock trades on Nasdaq in the US biotech segment, underscored how the genomic assay can inform management decisions for skin cancer patients, referencing a recent publication in the journal Dermatology and Therapy.

New melanoma test data published

In a June 2026 communication on its investor relations page, Castle Biosciences reported that updated real-world evidence supports the use of its DecisionDx-Melanoma test to refine risk stratification for cutaneous melanoma patients. The company pointed to outcomes data that link the test’s gene expression profile results with metastasis-free survival in routine clinical practice. Castle Biosciences investor relations update

The DecisionDx-Melanoma assay, which uses gene expression profiling on tumor tissue, is designed to classify patients into lower and higher risk categories for recurrence and metastasis beyond traditional staging criteria such as Breslow thickness and sentinel lymph node status. The latest publication summarizes physician decision changes in surveillance imaging and follow-up intensity when clinicians integrate test results alongside National Comprehensive Cancer Network risk factors.

Biotech peer context and analyst view

Castle Biosciences sits within the US diagnostics and genomics-focused biotech cohort that includes names such as Exact Sciences and Guardant Health. On Nasdaq, investors track the stock amid a broader sector that has seen alternating risk-on and risk-off phases tied to interest-rate expectations and reimbursement news. Recent market commentary from healthcare-focused analysts has emphasized that adoption of genomic tests like DecisionDx-Melanoma depends on guideline integration and payer coverage stability. Analyst and market commentary on biotech diagnostics stocks

For Castle Biosciences, consensus data compiled by independent platforms show a predominantly positive analyst stance, with the majority of covering brokers rating the stock Buy or Outperform and framing it as a specialized player in dermatologic oncology diagnostics. Price targets in these reports typically hinge on projected test volume growth for DecisionDx-Melanoma and other pipeline assays, plus progress in evidence generation capable of influencing clinical practice guidelines.

How Castle Biosciences earns its revenue

Castle Biosciences generates revenue primarily by providing genomic assays that assist physicians in managing dermatologic cancers and related conditions. Its flagship DecisionDx-Melanoma test analyzes gene expression in melanoma tissue to estimate the risk of metastasis, thereby guiding decisions on surveillance imaging and follow-up schedules for diagnosed patients.

Where the stock trades currently

Castle Biosciences shares trade on Nasdaq under the ticker CSTL. As of the latest available quote on a US market data provider on 2026-06-26, 19:15, the stock changed hands at around 25.40 USD in regular trading, with intraday movements reflecting broader sentiment toward small and mid-cap biotech names.

Castle Biosciences at a glance

• Company: Castle Biosciences Inc.
• ISIN: US14843C1053
• WKN: A2P6G4
• Ticker: CSTL
• Trading venue: Nasdaq
• Price (as of 2026-06-26, 19:15): 25.40 USD
• Market cap: approximately 700 million USD (as of 2026-06-26)
• Sector / industry: Health Care - Biotechnology / Diagnostics
• Index membership: not a member of major headline indices such as the S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.